Mumbai, Feb. 19 -- In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations.

"Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines," Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract develo...